Fierce Pharma

JUNE 12, 2023

market without a patent infringement challenge by early 2025 thanks to a new settlement. 21, 2025. Another biosimilar product copying Johnson & Johnson’s top-selling drug Stelara may enter the U.S. Following a deal with Amgen, J&J has granted Alvotech and Teva a license to launch their Stelara biosimilar no later than Feb.

Marketing 324

Marketing 324

Fierce Pharma

MAY 28, 2024

A recently announced $900 million restructuring drive is already making waves at Takeda, wi | From early July to March 2025, the Japanese drugmaker will cut 495 staffers at its Cambridge location and 146 in Lexington, Massachusetts. Takeda is the largest life sciences employer in the state.

344

344

Fierce Pharma

AUGUST 9, 2024

With Gilead's stated focus to grow in oncology, the company's recent quarterly updates have placed a heavy emphasis on its developments in the cancer space. | The HIV-focused drugmaker looks to position its long-acting Sunlenca as a prime PrEP option after the med aced a phase 3 study.

Marketing 299

Marketing 299

Fierce Pharma

APRIL 23, 2024

The recent Big Pharma CEO, known for steering the $74 billion acquisition of Celgene, has been proposed as the new chair at Novartis for 2025. . | Giovanni Caforio, M.D., is lining up a new gig soon after handing all his Bristol Myers Squibb leadership roles in March.

Pharma 349

Pharma 349

Fierce Pharma

OCTOBER 29, 2024

Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no different. Meanwhile, the company also scrapped plans to expand its topical JAK Opzelura into two other skin disorders.

Sales 302

Sales 302

Fierce Pharma

JANUARY 3, 2024

As the J.P. Morgan Healthcare Conference kicked off in San Francisco, EY released its annual report on the industry's dealmaking firepower. | As the J.P. Morgan Healthcare Conference kicked off in San Francisco, EY released its annual report on the industry's dealmaking firepower.

Healthcare 312

Healthcare Healthcare Sales 312

MedCity News

DECEMBER 1, 2024

in 2025 appeared first on MedCity News. Global medical costs are expected to rise by double digits for the third year in a row, according to a recent survey from WTW. The post Report: Global Medical Costs Projected to Rise by 10.4%

Medical 116

Medical Healthcare Healthcare 116

Fierce Pharma

JUNE 5, 2024

billion in costs by the end of 2025, a company spokesperson said over email. . | Starting this month, BMS will begin the process of laying off around 863 employees in Lawrenceville, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) alert from the state. The move forms part of BMS’ campaign to shave off $1.5

321

321

Fierce Pharma

AUGUST 7, 2024

In its quarterly earnings presentation, the Danish company said that after discussions with the FDA, it has pulled its filing and expects to resubmit in early 2025. . | Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold.

FDA 316

FDA Patients 316

MedCity News

NOVEMBER 11, 2024

The post A Sneak Peek of INVEST 2025 Agenda appeared first on MedCity News. Among the topics INVEST will highlight are AI in life sciences, the investor perspective in healthcare and strategic priorities for hospitals.

Healthcare 115

Healthcare Healthcare Biopharma 115

Fierce Pharma

OCTOBER 18, 2024

Integrated Patient Support Services, IQVIA | The 2025 Medicare Part D redesign will eliminate the “donut hole” and reduce out-of-pocket costs. Nancy McGee, VP & GM U.S. Patient Support Services, IQVIAJennifer Millard, VP U.S. Patient support is crucial for a smooth transition and better patient outcomes.

Patients 130

Patients 130

Fierce Pharma

OCTOBER 31, 2024

billion restructuring initiative that runs through 2025 may not be the end of the company’s ongoing efficiency push. | Bristol Myers' $1.5 billion restructuring initiative that runs through 2025 may not be the end of the company's ongoing efficiency push. Bristol Myers’ $1.5

325

325

Fierce Pharma

AUGUST 19, 2024

With its rapid development of the Jynneos vaccine, Bavarian | After the WHO declared mpox a global health emergency for the second time in 25 months, Bavarian Nordic said it could ramp up manufacturing to supply 12 million doses of its Jynneos vaccine through 2025 to contain the virus in Africa.

Manufacturing 278

Manufacturing 278

Fierce Pharma

NOVEMBER 1, 2023

But the new product will not launch until 2025 because of a settlement the companies made earlier this year, which delayed the launch in exchange for J&J dropping a patent infringement lawsuit. The FDA has signed off on Amgen’s biosimilar version of Johnson & Johnson’s autoimmune standout Stelara. |

FDA 314

FDA 314

PharmaVoice

OCTOBER 1, 2024

Mark your calendars for the most important industry conferences in 2025.

Pharma 101

Pharma 101

Fierce Pharma

NOVEMBER 27, 2024

Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will have to first face the agency’s Oncologic Drugs Advisory Committee ( | The agency's Oncologic Drugs Advisory Committee is set to discuss the treatment and its phase 3 CABINET study in March ahead of the FDA's planned (..)

FDA 246

FDA 246

Fierce Pharma

MARCH 21, 2024

The drugmaker's commitment will start by January 1, 2025, and follows similar moves by peers Boehringer Ingelheim and AstraZeneca. Amid congressional scrutiny on U.S. | Before the pledges, the companies—and Teva—caught Senate heat over high U.S. inhaler prices.

264

264

Fierce Pharma

APRIL 30, 2024

While an ongoing production expansion push for Eli Lilly's popular tirezeptide-based medicines Mounjaro and Zepbound should help out with perpetual supply strains later this year, the expected | While Eli Lilly's supply for Mounjaro and Zepbound is scheduled to increase during the second half of the year, demand is still expected to outpace (..)

Medicine 278

Medicine 278

Fierce Pharma

SEPTEMBER 11, 2023

Versions from Amgen, Teva and Alvotech are expected to launch in early 2025. . | The blockbuster inflammatory med's patents begin to expire this year, leaving biosimilar makers scrambling for a piece of the large market.

Marketing 298

Marketing 298

Fierce Pharma

AUGUST 19, 2024

. | The agency granted a broad regulatory exclusivity to rival United Therapeutics and its Tyvasvo DPI, leaving Liquidia's Yutrepia, which uses the same active drug, in FDA limbo until 2025.

FDA 264

FDA 264

Fierce Pharma

AUGUST 26, 2024

When CVS Caremark removed AbbVie’s Humira from its national commercial formularies back in April, biosimilar prescriptions picked up at a whirlwind pace. Following CVS Caremark's lead, Cigna's pharmacy benefit manager unit will nix Humira from formularies in favor of Humira biosimilars from Boehringer Ingelheim, Teva and Sandoz.

Prescription 264

Prescription Management Leads 264

Fierce Pharma

AUGUST 23, 2023

In October of last year, GSK laid out a plan to double its business in China by 2025, with much of that expansion dependent upon the succe | In October of last year, GSK laid out a plan to double its business in China by 2025, with much of that expansion dependent upon the success of shingles vaccine Shingrix.

246

246

Fierce Pharma

JUNE 10, 2024

The FDA assigned the subcutaneous Leqembi application a Prescription Drug User Fee Act decision date of January 25, 2025. About a month after Eisai initiated a rolling FDA application for its subcutaneous form of Leqembi, the U.S. agency has accepted the filing. |

FDA 241

FDA Prescription 241

Fierce Pharma

OCTOBER 7, 2024

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | The long-acting HIV PrEP maker pledged to make at least 2 million more doses available for low-and middle-income countries in 2025 and 2026.

Healthcare 246

Healthcare Healthcare 246

Fierce Pharma

OCTOBER 24, 2023

The company expects a decision in the first quarter of next year and is making plans to launch the treatment in the 2024-2025 flu season. The FDA has accepted AZ’s supplemental biologics license application (sBLA) for self-administered FluMist Qudrivalent.

FDA 290

FDA Marketing 290

pharmaphorum

JULY 8, 2022

That spend is due to reach of $3 billion by 2025, according to GlobalData analyst Kitty Whitney, who notes that there has been a steady stream of startups formed in the last three to four years to tap into the emerging AI market. The post Pharma’s spend on AI in drug discovery ‘could top $3bn by 2025’ appeared first on.

Marketing 131

Marketing Pharma Education Medicine 131

pharmaphorum

OCTOBER 5, 2023

Moderna eyes 2025 approval for COVID, flu combination jab Phil.Taylor Thu, 05/10/2023 - 08:38 Bookmark this

105

105

Fierce Pharma

DECEMBER 17, 2024

Jazz aims to complete its search for a CEO successor by the end of 2025, after which Cozadd will stay on board as the drugmaker's board chair. . | Current helmsman Bruce Cozadd plans to retire from his role at Jazz Pharmaceuticals in the next 12 months, the company said Monday.

Pharmaceutical 256

Pharmaceutical 256

Fierce Pharma

JUNE 29, 2023

Much of that momentum hinges on Sanofi’s pipeline, where the company is targeting an “accelerated pace of innovation” in a bid to launch at least five phase 3 vaccine programs by 2025.

Sales 264

Sales 264

Fierce Pharma

JULY 10, 2023

After a Delaware federal court ruled a Novartis combination patent on big-selling cardiovascular drug Entresto is invalid, the company pledged to continue its efforts to block generics with an appe | After a Delaware district court ruled a 2025 Entresto combination patent is invalid, Novartis will head to the U.S.

269

269

MedCity News

NOVEMBER 19, 2024

The post Managing the Specialty Drug Cost Challenge: Is Your Pharmacy Benefits Strategy Ready for 2025? What concrete strategies should employers pursue to control rising costs while ensuring the best member experience and clinical outcomes? appeared first on MedCity News.

Management 119

Management Pharmaceutical Biopharma Pharma 119

MedCity News

DECEMBER 18, 2024

The post Future Trends for Clinical Trials in 2025 and Beyond appeared first on MedCity News. Four key predictions for the future of clinical trials, examining how these changes will revolutionize the speed, efficiency, and reliability of bringing life-saving treatments to market.

Marketing 66

Marketing Biopharma Pharma 66

MedCity News

DECEMBER 16, 2024

Zocdoc CEO Oliver Kharraz has some predictions about how healthcare will change in 2025 including the rise of cash-pay services and the potential restructuring of Amazons healthcare assets. The post Zocdoc CEO Predicts 3 Ways the Healthcare Industry Will Change in 2025 appeared first on MedCity News.

Healthcare 61

Healthcare Healthcare 61

European Pharmaceutical Review

DECEMBER 11, 2024

LOG Pharma Primary Packaging is set to present its new barrier eco line at Pharmapack Europe 2025. Pharmapack Europe 2025 The innovative design integrates pharma-grade HEALTH + resins with superior gas barrier properties. The new bottles for pharmaceuticals offer optimal oxygen scavenging.

Pharma 59

Pharma Government Competition Pharmaceutical 59

Fierce Pharma

DECEMBER 17, 2024

With Eylea biosimilar competition creeping in and Roches Vabsymo jockeying for market share in key indications, Regeneron is racing to carve out a new market for the high-dose version of its block | High-dose Eylea demonstrated non-inferiority to the original version of the drug in patients with macular edema following retinal vein occlusion, an indication (..)

Competition 140

Competition Marketing FDA Patients 140

pharmaphorum

MARCH 13, 2024

Prilenia Therapeutics is planning to file its Huntington’s disease drug pridopidine in the EU shortly, after mixed results in a phase 3 trial.

111

111

Eversana Intouch

NOVEMBER 18, 2024

In this report, 15 of our experts examine the current impact of each of these three forces, predict how you’ll see their effects in 2025 and give recommendations for how to make these market forces work for you. Over the coming weeks, you’ll be seeing a lot of forecasts for 2025. And this isn’t an anonymous think piece.

Marketing 59

Marketing Pharma Competition Patients 59